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Abstract
Background: As well as imposing an economic burden on affected households, the high costs related to tuberculosis
(TB) can create access and adherence barriers. This highlights the particular urgency of achieving one of the End TB
Strategy’s targets: that no TB-affected households have to face catastrophic costs by 2020. In Indonesia, as elsewhere,
there is also an emerging need to provide social protection by implementing universal health coverage (UHC). We
therefore assessed the incidence of catastrophic total costs due to TB, and their determinants since the implementation
of UHC.
Methods: We interviewed adult TB and multidrug-resistant TB (MDR-TB) patients in urban, suburban and rural areas of
Indonesia who had been treated for at least one month or had finished treatment no more than one month earlier.
Following the WHO recommendation, we assessed the incidence of catastrophic total costs due to TB. We also analyzed
the sensitivity of incidence relative to several thresholds, and measured differences between poor and non-poor
households in the incidence of catastrophic costs. Generalized linear mixed-model analysis was used to identify
determinants of the catastrophic total costs.
Results: We analyzed 282 TB and 64 MDR-TB patients. For TB-related services, the median (interquartile range) of
total costs incurred by households was 133 USD (55–576); for MDR-TB-related services, it was 2804 USD (1008–4325).
The incidence of catastrophic total costs in all TB-affected households was 36% (43% in poor households and 25% in
non-poor households). For MDR-TB-affected households, the incidence was 83% (83% and 83%). In TB-affected
households, the determinants of catastrophic total costs were poor households (adjusted odds ratio [aOR] = 3.7,
95% confidence interval [CI]: 1.7–7.8); being a breadwinner (aOR = 2.9, 95% CI: 1.3–6.6); job loss (aOR = 21.2;
95% CI: 8.3–53.9); and previous TB treatment (aOR = 2.9; 95% CI: 1.4–6.1). In MDR-TB-affected households, having an
income-earning job before diagnosis was the only determinant of catastrophic total costs (aOR = 8.7; 95% CI: 1.8–41.7).
Conclusions: Despite the implementation of UHC, TB-affected households still risk catastrophic total costs and further
impoverishment. As well as ensuring access to healthcare, a cost-mitigation policy and additional financial protection
should be provided to protect the poor and relieve income losses.
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Background
The estimated 1.4 million deaths to tuberculosis (TB)
in 2015 exemplify the persisting burden of TB. With a
global incidence that declines by only 2% annually
worldwide, slow progress is being made towards the
target for eliminating the disease by 2035 [1, 2]. These
stark figures show that global action should be taken to
adjust strategies and to combine initiatives such as pro-
moting clinical adherence and providing socio-economic
support [3, 4].
Although TB patients in most high TB-burden
countries have free access to anti-TB drugs, they
often incur high costs for travel and food, and suffer
income losses that can amount to over half of annual
household income [5, 6]. Such financial hardship creates
an adherence barrier to diagnostic procedures and treat-
ment, resulting in poor outcomes and increasing the risk
of transmission in the community [5–8]. Accessing TB-
related services also has economic consequences. The job
or income losses experienced by TB patients, especially
those in the productive age group, can reduce the financial
capacity of their households and cast them into the
poverty trap [9–11].
To address the socio-economic determinants and
financial impact of TB, the WHO End TB Strategy
acknowledges the need for social protection by
setting a clear first milestone that no TB-affected
families should face catastrophic TB-related costs
after 2020 [1, 2]. This target complements the Sus-
tainable Development Goal (SDG) of achieving uni-
versal health coverage (UHC) through the provision
of more affordable and high-quality healthcare ser-
vices [3, 12].
Indonesia started its UHC program in 2014 by offering
national public insurance and by engaging more private
providers in the network managed by the Social Se-
curity Agency (Badan Penyelenggara Jaminan Sosial,
BPJS), the Ministry of Health and the Ministry of So-
cial Affairs. It is assumed that direct medical costs,
which are costs incurred for diagnostic tests, treat-
ment, and follow-up tests, will be reduced by the na-
tional insurance scheme, which covers all medical
costs in primary to tertiary care, including TB-related
services [13]. Due to Indonesians people’s strong pref-
erence for seeking care with private providers, the in-
volvement of more private providers in the BPJS
network is also expected to have an impact by redu-
cing medical expenses which were reportedly three
times higher than those charged by public providers
[14], and by reducing the number of people who de-
velop TB but are not diagnosed or cannot access TB
care services that conform with International Stand-
ard of Tuberculosis Care (ISTC) [9].
Accessing healthcare services is time-consuming
and costly [9, 10, 15–17]. The Indonesian National
TB Program (NTP) has attempted to provide support
in the form of food/nutritional supplementation and
travel vouchers, for example, in addition to diagnostic
examination and drug costs coverage. However, the
policy has changed and the support has been re-
stricted or even ended. It leaves direct non-medical
costs including travel and food/nutritional supplement
costs uncovered and can lead to catastrophic health
expenditure (CHE). As TB and multidrug-resistant TB
(MDR-TB) require a long period of treatment, and
also worsen health status, TB patients also suffer from
job or income losses that aggravate the risk of cata-
strophic costs and barriers to treatment adherence.
The WHO has introduced a new term “catastrophic
total costs” as the TB-specific indicator that differs in
essence from CHE. CHE is defined as the share of
the population spending more than a given threshold
and focuses on direct cash spending or out-of-pocket
(OOP) payments made by household to improve or
restore health of household members. The TB-specific
indicator of “catastrophic total costs” incorporates dir-
ect medical costs, direct non-medical costs and over-
all indirect costs, and helps to capture the economic
burden specific for TB [18, 19]. It is therefore crucial
for TB elimination programs to identify the main cost
drivers, monitor financial hardship, and establish
which further health and social policy measures
should be taken [18]. For this reason, we aimed not
only to measure the incidence of catastrophic total
costs caused by TB and the sensitivity of the inci-
dence relative to a range of specific thresholds, but
also to assess differences between poor and non-poor
households in terms of the incidence of catastrophic
total costs and to identify the determinants of cata-
strophic total costs since Indonesia’s implementation
of UHC.
Methods
Study design
From July to September 2016, a stratified clustered
sampling design was used to enroll TB patients in an
urban district (Jakarta), a suburban district (Depok)
and a rural district (Tasikmalaya). Per district, we ran-
domly selected 6–8 primary health centers (PHCs)
linked with the NTP. Until reaching our predeter-
mined sample size, we enrolled all the consecutive TB
patients who attended these PHCs and who also met
our inclusion criteria: they were aged 18 years or
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above, had undergone the adult diagnostic procedure,
had been treated for at least one month or had fin-
ished treatment no more than a month previously,
and had signed informed consent. Extra-pulmonary
TB cases were excluded. Assuming a power of 0.80, a
1:1:1 ratio of urban to suburban to rural districts, and
that the incidence of TB-related catastrophic total
costs in each district was 20%, 25%, and 30%, we col-
lected a minimum of 90 patients in each district.
MDR-TB patients were enrolled at Persahabatan
Hospital, an MDR-TB referral hospital in Jakarta. We
selected those adult MDR-TB patients who came to
the hospital consecutively, had undergone MDR-TB
treatment in the hospital for at least one month, had
recorded a diagnostic result as MDR-TB, either by
GenXpert or sputum culture; and had signed the in-
formed consent form.
Cost measurement
Ten medical students and public health graduates
were recruited and trained as interviewers. Using the
adapted Bahasa Indonesia version of the Tool to
Estimate Patient Costs, they then interviewed pa-
tients and/or their drug observer, i.e., a family
member who was selected as the patient’s direct-
observation-of-treatment supporter [20, 21]. Retro-
spectively, each respondent reported all types of cost
related to the TB care services they had incurred
during the pre-diagnostic, diagnostic, and treatment
phases (Table 1).
Pre-diagnostic and diagnostic costs
The pre-diagnostic and diagnostic costs were the sum
of all the direct and indirect costs incurred for pre-
diagnostic and diagnostic visits. The direct costs
included all OOP payments incurred after any reim-
bursement for medical fees and all non-medical ex-
penditures made by patients or their guardian (i.e., a
family member who accompanied them during visits).
Indirect costs consisted of the income loss reported
by patients and guardians.
Treatment costs
The costs of anti-TB drugs are covered by the NTP.
We calculated the administration or registration fee,
food and travel costs that were typical for each visit.
To estimate the costs per month, we then multiplied
these cost items by the number of visits per month.
Any travel vouchers given to patients were included
as a deduction of travel costs. We also summed
treatment evaluation costs according to the number
of evaluation tests conducted. We estimated patient’s
income losses on the basis of income changes re-
ported after diagnosis. To avoid underestimates for
people such as taxibike drivers who continued to
earn uncertain monthly incomes from informal jobs,
we also estimated time-loss value. To calculate this
time-loss value, we used the following formula:
round trip in minutes for a typical visit × patient’s
income loss per minute × the number of visits per
month [5].
We interviewed some patients in the intensive treat-
ment phase and others in the continuation treatment
phase. For patients interviewed during the intensive
phase, we obtained the reported costs of the intensive
phase from the patient and estimated the costs in the
continuation phase on the basis of other patients’
data in other PHCs within a same district. For pa-
tients interviewed during the continuation phase, we
obtained reported costs from the patient in both the
intensive and continuation phases, then extrapolated
the reported costs to obtain the total costs of both
phases. To estimate the entire treatment costs, we ex-
trapolated the monthly costs according to the inter-
nationally defined durations of the intensive and
continuation phases: (a) two months (for the intensive
phase) and four months (for the continuation phase)
of new TB treatment (Category I); (b) three and five
Table 1 Definition of costs and income used in this study
Variables Definition Direct costs Indirect costs
Pre-diagnostic and diagnostic costs All types of cost incurred during the
period between the onset of symptoms
and diagnosis with TB in public or
private healthcare facilities, at a pharmacy,
or by a practitioner of alternative medicine.
Medical: Costs of consultation,
administration, laboratory tests,
X-ray examinations, and drugs.
Non-medical: Costs of food and
travel for patient and/or guardian.
Patient’s and guardian’s
income losses.
Treatment costs All types of cost incurred after being
diagnosed and treated for TB, includes
the costs of hospitalization and
adverse events.
Medical: Costs of administration,
evaluation (laboratory test, X-ray
examination, or others),
hospitalization, and adverse events.
Non-medical: Costs of food and
travel (for patient and/or guardian),
and food supplements.
Patient’s and guardian’s
income losses.
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months for re-treatment (Category II), and (c) eight
and twelve months for MDR-TB treatment [5, 22, 23].
We summed other direct medical costs, e.g. hos-
pitalization and any adverse event costs, that were
uncovered by health insurance. We also calculated
monthly nutritional/food supplement costs incurred by
patients, such as vitamins, fruit, milk, meat, or other
supplements consumed as a result of TB treatment.
To measure income loss, we established the house-
hold income earned through the incomes of patients
and other family members, through government aid,
and through other income, before and after the pa-
tients had been diagnosed with TB. A household
earning below 1.9 USD per capita per day was classi-
fied as a poor household [24]. As many Indonesians
live in extended families that may have more than
one income earner per household, we defined a pa-
tient as breadwinner if his/her income was at least
10% higher than that of any other family member
[25, 26]. All costs and incomes were converted to
US dollars using the average exchange rate calcu-
lated by the World Bank for 2015 (1 USD = 13
389.41 IDR) [27].
Catastrophic total costs
The WHO protocol takes two approaches to measure
the percentage of patients experiencing catastrophic
total costs. The first is based on total costs, and de-
fines catastrophic total costs as total costs (direct and
indirect costs) incurred by household that exceed 20%
of the household’s annual income. The second ap-
proach defines catastrophic total costs as the share of
TB patients who experience dissaving by taking a loan
or selling property or livestock to deal with costs re-
lated to TB [18]. In this study, we applied the first ap-
proach. Total costs due to TB were defined as the sum
of the OOPs incurred for medical diagnosis and treat-
ment (OOPM), OOPs for non-medical expenditures
related to the use of TB care services (OOPNM), and pa-
tients’ and guardians’ reported income losses or time
losses valuations (IN), net of any reimbursement and wel-
fare payments. The denominator was reported annual
household income in the year before diagnosis with
TB [18].
As well as measuring the incidence of catastrophic
total costs, referred to here as the headcount (H), we
established the sensitivity of this headcount (i.e. inci-
dence) relative to thresholds of 5%, 10%, 15%, 20%, and
25% as used in other previous studies [10, 11]. For each
threshold, we also calculated mean gap (G) and mean
positive gap (MPG). The G indicates the average amount
by which payments, as a proportion of household in-
come, exceed the threshold. The MPG is equal to G/H,
and helps to identify how excessive the total costs are
by indicating the excess expenditure per household
that experiences catastrophic total costs [7, 11, 28,
29].
To analyze the different pictures provided by the
catastrophic total cost approach and the CHE ap-
proach, we compared the H’s, G’s, and MPGs per
threshold between these two approaches [30, 31]. Per
threshold, we also analyzed differences between poor
and non-poor households in the H’s, G’s, and MPGs
of catastrophic total costs.
Fourteen patient variables were examined as potential
determinants of catastrophic total costs: (1) district
(urban, suburban, rural), (2) household income (poor
and non-poor), (3) sex, (4) age group, (5) educational
level (primary school as “low,” junior school and senior
high school as “intermediate”; and college and univer-
sity as “high”), (6) being a family breadwinner, (7) hav-
ing had an income-earning job before diagnosis, (8)
having insurance before being diagnosed, (9) having
had previous TB treatment, (10) HIV status, (11)
hospitalization for the current TB treatment, (12) first
contact with the facility after having symptoms of TB,
(13) taking Food supplementation, and (14) experien-
cing adverse effects.
Data analysis
To ensure data quality, we used Microsoft Excel 2010 and
EpiInfo version 7 (CDC, Atlanta) to double-enter and to
check the data. Abnormally distributed data were dis-
played as median (inter-quartile range [IQR, q25-q75]),
while categorical variables were shown as numbers and
proportions (%). The Mann-Whitney test was used to
compare all types of the cost incurred for access TB-
related services between poor and non-poor households.
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Table 2 Patient characteristics
Characteristics TB (%) MDR-TB (%)
Total Urban Suburban Rural
Sex n = 282 n = 95 n = 90 n = 97 n = 64
Male 155 (55) 51 (54) 52 (58) 52 (54) 31 (48)
Female 127 (45) 44 (46) 38 (42) 45 (46) 33 (52)
Age in years
18–40 137 (49) 45 (47) 47 (52) 45 (46) 34 (53)
41–64 123 (44) 44 (46) 38 (42) 41 (42) 29 (45)
> 64 22 (8) 6 (6) 5 (6) 11 (11) 1 (2)
Educational level
Low 99 (35) 25 (26) 18 (20) 56 (58) 12 (19)
Intermediate 172 (61) 67 (71) 65 (72) 40 (41) 42 (65)
High 11 (4) 3 (3) 7 (8) 1 (1) 10 (16)
Household income
Poor 175 (62) 46 (48) 45 (50) 84 (87) 23 (36)
Non-poor 107 (38) 49 (52) 45 (50) 13 (13) 41 (64)
Breadwinner
Patient 124 (44) 48 (51) 38 (42) 38 (39) 25 (39)
Not patient 158 (56) 47 (49) 52 (58) 59 (61) 39 (61)
Income-earning job
Yes 201 (71) 73 (77) 61 (68) 67 (69) 49 (77)
No 81 (29) 22 (23) 29 (32) 30 (31) 15 (23)
Job loss
Job loss 64 (23) 17 (18) 18 (20) 29 (30) 34 (53)
No job loss 218 (77) 78 (82) 72 (80) 68 (70) 30 (47)
Having health insurance
Yes 176 (62) 73 (77) 63 (70) 40 (41) 56 (87)
No 106 (38) 22 (23) 27 (30) 57 (59) 8 (13)
Insurance type n = 176 n = 73 n = 63 n = 40 n = 56
BPJS, (paid by governmenta) 119 (68) 52 (71) 33 (52) 34 (85) 24 (43)
BPJS, (self-paidb) 53 (30) 19 (26) 28 (44) 6 (15) 32 (57)
Private insurance 4 (2) 2 (3) 2 (3) 0 (0) 0 (0)
Monthly income n = 201 n = 73 n = 61 n = 67 n = 49
Paid regularly 90 (45) 32 (44) 39 (64) 19 (28) 34 (69)
Uncertain 105 (52) 37 (51) 20 (33) 48 (72) 13 (27)
Others 6 (3) 4 (5) 2 (3) 0 (0) 2 (4)
n = 282 n = 95 n = 90 n = 97 n = 64
Type of TB
Pulmonary, smear + 186 (66) 70 (74) 62 (69) 54 (56) 64 (100)
Pulmonary, smear - 80 (28) 23 (24) 24 (27) 33 (34) 0 (0)
Pulmonary, smear unknown 16 (6) 2 (2) 4 (4) 10 (10) 0 (0)
Therapy phase
Intensive phase 134 (48) 38 (40) 51 (57) 45 (46) 37 (58)
Continuation phase 148 (52) 57 (60) 39 (43) 52 (54) 27 (42)
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We used random effects to adjust for our cluster
sampling design (19 PHCs), and used the generalized
linear mixed model to examine determinants of the
incidence with which TB-affected households faced
catastrophic total costs. For MDR-TB cases, we used
binary logistic regression to examine the determi-
nants of catastrophic total costs. In the univariate
analysis, we estimated the significance (P), the crude
odds ratios (cORs), and their 95% confidence inter-
vals (CIs). To identify the best model and estimate
the significances, adjusted ORs (aORs) and the 95%
CIs of the determinants, we included all variables
with a P < 0.25 in the univariate analysis in a multi-
variable analysis.
Ethical issues
Before the interview, all respondents received written
and oral explanations of the study and signed an
informed-consent form. Ethical clearance for this
study was provided by the Ethical Committee at the
Faculty of Medicine of Universitas Indonesia–Cipto
Mangunkusumo Hospital, Jakarta, Indonesia (No.
416/UN2.F1/ETIK/VI/2016) and the Ethical Commit-
tee at Persahabatan Hospital, Jakarta, Indonesia (No.
DL.01.03/II.3/3817/2016).
Results
Patients characteristics
As eight (3%) of the 354 eligible TB and MDR-TB patients
did not report their household income, we analyzed the
data from 346 patients (282 TB and 64 MDR-TB patients)
(Table 2). Most patients were of working age, had an inter-
mediate educational background, and lived in a poor
household. Thirty-two percent of the TB patients with an
income-earning job had lost their job after diagnosis,
against 69% of the MDR-TB patients. Less than one-third
(23%) of the TB patients in the urban study area did not
have health insurance, compared with 59% in the rural
study area. Most patients had smear-positive TB and were
divided equally according to the phase of treatment.
In spite of the availability of primary care, most TB pa-
tients first sought care in a hospital (78%). Our results also
show that a high proportion of TB patients went first to a
private provider; even in rural areas, this figure was 46%.
Investigation of the reasons for not choosing a public pro-
vider showed that the distance to the public facility was a
prominent issue, as were personal preference and familiar-
ity with a specific private facility (See Additional file 2).
TB-related total costs
The median (IQR) of total costs was 133 USD in the TB
group (55–576) and 2804 USD in the MDR-TB group
Table 2 Patient characteristics (Continued)
Characteristics TB (%) MDR-TB (%)
Total Urban Suburban Rural
HIV status
Positive 6 (2) 5 (5) 1 (1) 0 (0) 0 (0)
Negative 92 (33) 51 (54) 17 (19) 24 (25) 32 (50)
Not tested/unknown 184 (65) 39 (41) 72 (80) 73 (75) 32 (50)
Hospitalization
Yes 39 (14) 11 (12) 13 (14) 15 (16) 34 (53)
No 243 (86) 84 (88) 77 (86) 82 (84) 30 (47)
Previous TB treatment
Yes 58 (21) 29 (31) 20 (22) 9 (9) 56 (87)
No 224 (79) 66 (69) 70 (78) 88 (91) 8 (13)
Completed previous TB treatment n = 58 n = 29 n = 20 n = 8 n = 56
Yes 35 (61) 19 (65) 10 (50) 6 (75) 34 (61)
No 22 (39) 10 (35) 10 (50) 2 (25) 22 (39)
First contact
Public hospital 127 (45) 51 (54) 40 (44) 36 (37) 29 (45)
Private hospital 94 (33) 26 (27) 26 (29) 42 (43) 2 (3)
Primary health center 32 (11) 11 (12) 10 (11) 11 (11) 25 (39)
Private clinic 20 (7) 4 (4) 13 (14) 3 (3) 8 (13)
Other facility 9 (3) 3 (3) 1 (1) 5 (5) 0 (0)
aTheir national public insurance (BPJS) premiums were paid by the government; bThey paid national public insurance (BPJS) premium out of their pocket
Fuady et al. Infectious Diseases of Poverty  (2018) 7:3 Page 6 of 14
Ta
b
le
3
C
os
ts
of
pr
e-
di
ag
no
si
s,
di
ag
no
si
s,
an
d
tr
ea
tm
en
t
of
TB
st
ra
tif
ie
d
by
in
co
m
e
at
ho
us
eh
ol
d
le
ve
l;
m
ed
ia
n
(IQ
R)
in
U
SD
C
os
ts
TB
P
M
D
R-
TB
P
To
ta
l
Po
or
N
on
-P
oo
r
To
ta
l
Po
or
N
on
-P
oo
r
Pr
ed
ia
gn
os
is
an
d
di
ag
no
si
s
D
ire
ct
co
st
s
11
(3
–2
1)
12
(4
–2
2)
10
(2
–2
1)
0.
85
7
21
(7
–4
7)
15
(5
–3
5)
28
(7
–6
7)
0.
16
4
In
di
re
ct
co
st
s
1
(0
–7
)
1
(0
–7
)
0
(0
–4
)
0.
13
6
4
(0
–1
6)
1
(0
–8
)
5
(0
–1
9)
0.
14
1
Pa
tie
nt
’s
in
co
m
e
lo
ss
0
(0
–0
)
0
(0
–2
)
0
(0
–0
)
0.
08
9
0
(0
–0
)
0
(0
–0
)
0
(0
–2
)
0.
42
8
G
ua
rd
ia
n’
s
in
co
m
e
lo
ss
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
39
3
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
65
0
To
ta
l
13
(5
–3
0)
15
(5
–2
9)
12
(3
–3
1)
0.
75
0
27
(1
3–
62
)
20
(1
1–
35
)
32
(1
4–
85
)
0.
04
9
Tr
ea
tm
en
t
D
ire
ct
m
ed
ic
al
co
st
s
0
(0
–6
)
2
(0
–6
)
0
(0
–3
)
0.
85
1
15
(0
–7
8)
9
(0
–6
0)
17
(0
–1
16
)
0.
32
8
A
dm
in
is
tr
at
io
n
co
st
s
0
(0
–2
)
0
(0
–3
)
0
(0
–2
)
0.
42
6
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
45
4
Tr
ea
t m
en
t
ev
al
ua
tio
n
co
st
s
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
10
4
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
18
8
H
os
pi
ta
liz
at
io
n
co
st
s
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
74
8
8
(0
–6
8)
0
(0
–6
0)
15
(0
–7
8)
0.
49
9
A
dv
er
se
ef
fe
ct
co
st
s
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
73
9
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
86
9
D
ire
ct
no
n-
m
ed
ic
al
co
st
s
33
(8
–9
7)
29
(9
–9
0)
40
(8
–1
17
)
0.
66
6
85
6
(4
30
–1
42
7)
94
1
(4
30
–1
25
5)
80
7
(4
30
–1
54
6)
0.
69
0
Tr
av
el
co
st
s
7
(1
–1
7)
9
(0
–2
1)
4
(1
–1
0)
0.
00
4
40
3
(1
08
–8
07
)
40
3
(5
4–
80
7)
40
3
(1
08
–8
07
)
0.
45
7
Fo
od
co
st
s
0
(0
–5
)
0
(0
–6
)
0
(0
–4
)
0.
66
0
26
9
(0
–4
59
)
21
5
(0
–4
03
)
26
9
(0
–5
38
)
0.
44
2
Fo
od
su
pp
le
m
en
t
co
st
s
13
(0
–6
7)
7
(0
–5
4)
20
(0
–9
0)
0.
64
1
17
9
(4
–3
47
)
17
9
(9
0–
44
8)
17
9
(0
–2
91
)
0.
41
6
In
di
re
ct
co
st
s
8
(0
–4
48
)
11
(0
–3
58
)
4
(0
–6
02
)
0.
23
6
13
44
(2
–2
57
7)
26
9
(0
–1
8 8
2)
17
92
(2
02
–2
91
3)
0.
00
9
Pa
tie
nt
’s
in
co
m
e
lo
ss
2
(0
–4
48
)
2
(0
–3
58
)
1
(0
–6
02
)
0.
14
3
13
44
(2
–2
57
7)
26
9
(0
–1
61
3)
17
92
(2
–2
68
9)
0.
01
5
G
ua
rd
ia
n’
s
in
co
m
e
lo
ss
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
38
0
0
(0
–0
)
0
(0
–0
)
0
(0
–0
)
0.
46
5
To
ta
l
11
7
(3
3–
54
5)
10
8
(3
3–
45
1)
13
5
(3
2–
78
4)
0.
35
2
27
60
(9
89
–4
30
9)
12
44
(4
48
–3
35
2)
34
85
(1
85
1–
46
38
)
0.
01
2
To
ta
lc
os
ts
13
3
(5
5–
57
6)
13
2
(5
8–
49
2)
13
8
(4
5–
79
2)
0.
27
7
28
04
(1
00
8–
43
25
)
12
68
(4
61
–3
36
3)
35
06
(1
91
4–
47
99
)
0.
01
1
Fuady et al. Infectious Diseases of Poverty  (2018) 7:3 Page 7 of 14
(1008–4325) (Table 3). The treatment costs amounted to
88% of median total costs for TB patients and 98% for
MDR-TB patients. (Figure 1) Despite the low medians of
indirect costs and patients’ income loss, our results show
that once patients lost their jobs, they lost a lot of their
income. Among those who lost their jobs, average in-
come loss amounted to 80% of total costs. Instead, the
median annual income of TB and MDR-TB patients
(1344 USD and 2241 USD) were much lower than the
Indonesian GDP per capita in 2015 (3834 USD).
The differences in total costs between poor and non-
poor TB patients were not statistically significant. How-
ever, in non-poor households affected by MDR-TB, the
total costs were higher than in poor households, due
mainly to higher income losses.
Catastrophic total costs
At the 20% threshold, the incidence, i.e. headcount, of
catastrophic total costs was 36% for TB and 83% for
MDR-TB; this was similar to the respective incidences of
CHE at the 10% threshold (22% and 84%) (Table 4).
However, the catastrophic total costs approach consist-
ently showed higher mean gaps (G’s) both for TB (10%
vs. 4%) and MDR-TB (79% vs. 68%) than the CHE ap-
proach did.
There was an inverse association between catastrophic
total costs and household income. Although their me-
dian total costs were not significantly different, poor TB-
affected households, which had lower incomes, had
higher headcounts than non-poor households (43% vs.
25%, P = 0.006 when using the threshold of 20%)
Fig. 1 Costs incurred for TB-related services. Pre-diagnostic and diagnostic costs, treatment costs and total costs between poor and non-poor patients
in (a) TB groups and (b) MDR-TB groups; and costs incurred during treatment in (c) TB and (d) MDR-TB affected households. Means are indicated by
blue rhombs, medians by a horizontal line, q25 by the bottom horizontal line of each box, and q75 by the top horizontal line of each box
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(Table 5). The differences in incidence of catastrophic
total costs between poor and non-poor households were
also statistically significant with the thresholds of 10%
(P = 0.014), 15% (P = 0.006), and 25% (P = 0.009). For
MDR-TB, the incidence of catastrophic total costs was
similar for poor and non-poor households, irrespective
to the threshold used. At the same time, the G’s indicated
that poor households suffered more than non-poor house-
holds (138% vs. 45% when using threshold of 20%). As the
MPGs indicated, the gap was greater in poor households
that faced catastrophic total costs (167%).
Determinants of catastrophic total costs
With regard to catastrophic total costs among TB-
affected households, there were four determinants: poor
household (adjusted odds ratio [aOR] = 3.7; 95% confi-
dence interval [CI]: 1.7–7.8; P = 0.001); breadwinners
(aOR = 2.9; 95% CI: 1.3–6.6; P = 0.010); job loss (aOR =
21.2; 95% CI: 8.3–53.9; P < 0.001); and previous TB
treatment (aOR = 2.9; 95% CI: 1.4–6.1; P = 0.006)
(Table 6). Not being covered by health insurance was
not a determinant of catastrophic total costs in either
TB-affected or MDR-TB-affected households. With re-
gard to MDR-TB-affected households, the multivariable
analysis showed that the only determinant of cata-
strophic total costs in these households was having had
an income-earning job before diagnosis (aOR = 8.7; 95%
CI: 1.8–41.7; P = 0.007) (Table 7).
Discussion
Despite the implementation of UHC in Indonesia, there
is a high incidence of catastrophic total costs due to TB,
particularly among patients who live in poor households
and those who lose their jobs due to TB. In general, the
greatest contribution to total costs was made by travel
and food/nutritional supplementation costs. However,
losing both job and income after diagnosis was also a
critical point: once patients had lost their jobs, income
Table 5 Differences between poor and non-poor households in catastrophic total costs
Catastrophic
total costs
TB MDR-TB
10% 15% 20% 25% 10% 15% 20% 25%
Headcount
Poor (%) 57 50 43 37 96 87 83 78
Non-poor (%) 39 32 25 22 93 88 83 81
Total (%) 50 43 36 31 94 88 83 80
P 0.014 <0.006 0.006 0.009 0.111 0.117 0.115 0.121
Mean gap
Poor (%) 18 15 13 11 147 142 138 134
Non-poor (%) 8 6 5 3 54 50 45 41
Total (%) 14 12 10 8 88 83 79 75
Meanpositive gap
Poor (%) 32 30 30 30 154 164 167 171
Non-poor (%) 19 19 18 16 58 56 55 51
Total (%) 28 27 27 26 93 95 95 94
Table 4 The headcounts of catastrophic costs due to TB and the sensitivity of these headcounts
Catastrophic costs TB MDR-TB
5% 10% 15% 20% 25% 5% 10% 15% 20% 25%
Catastrophic total costsa
Headcount (%) 50 43 36 31 94 88 83 80
Mean gap (%) 14 12 10 8 88 83 79 75
Mean positive gap (%) 28 27 27 26 93 95 95 94
Catastrophic health expenditurea
Headcount (%) 42 22 16 12 94 84 69 61
Mean gap (%) 6 4 3 2 72 68 64 60
Mean positive gap (%) 14 18 19 17 77 81 93 98
aCatastrophic total costs approach incorporates all type of costs, i.e. direct medical costs, direct non-medical costs, and overall indirect costs, while the CHE
approach focuses only on direct cash spending or OOP payments made by household
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Table 6 Determinants of catastrophic total costs in TB cases
Determinants Catastrophic total costs P cOR (95% CI) P aOR (95% CI)
Yes % No %
Household income
Poor 75 43 100 57 0.006 2.20 (1.26–3.86) 0.001 3.68 (1.74–7.78)
Non-poor 27 25 80 75 1.00 1.00
District
Urban 35 37 60 63 1.00
Sub-urban 22 24 68 76 0.125 0.54 (0.25–1.19)
Rural 45 46 52 54 0.317 1.47 (0.69–3.16)
Sex
Male 57 37 98 63 0.710 1.10 (0.66–1.82)
Female 45 35 82 65 1.00
Age, years old
18–40 49 36 88 64 1.00
41–64 44 36 79 64 0.977 0.99 (0.59–2.67)
> 64 9 41 13 59 0.816 1.12 (0.43–2.90)
Educational level
Low 41 41 58 59 1.00
Intermediate 58 34 114 66 0.355 0.78 (0.45–1.33)
High 3 27 8 73 0.479 0.60 (0.14–2.51)
Breadwinner
Patient 65 52 59 48 <0.001 3.60 (2.16–6.00) 0.010 2.92 (1.29–6.60)
Not patient 37 23 121 77 1.00 1.00
Income-earning job
Yes 90 45 111 55 <0.001 4.66 (2.38–9.14) 0.881 1.08 (0.40–2.92)
No 12 15 69 85 1.00 1.00
Job loss
Job loss 51 80 13 20 <0.001 14.07 (6.84–28.93) <0.001 21.17 (8.31–53.90)
No job loss 51 23 167 77 1.00 1.00
Health insurance
No 43 41 63 59 0.390 1.26 (0.74–2.15)
Yes 59 34 117 66 1.00
HIV status
Negative 44 48 48 52 1.00
Positive 0 0 6 100 0.953 0.00 (0.00-~)
Not tested/unknown 58 32 126 68 0.863 0.46 (0.26–0.82)
Previous TB treatment
Yes 31 53 27 47 0.001 2.93 (1.56–5.48) 0.006 2.86 (1.35–6.05)
No 71 32 153 68 1.00 1.00
First contact with facility
Private facility 46 37 77 63 0.622 1.14 (0.68–1.89)
Public facility 56 35 103 65 1.00
Hospitalization
Yes 15 38 24 62 0.685 1.16 (0.56–2.38)
No 87 36 156 64 1.00
Fuady et al. Infectious Diseases of Poverty  (2018) 7:3 Page 10 of 14
loss became the main driver of total costs. These find-
ings emphasize the importance not only of providing
travel and nutritional supports but also social protection
for those who lose income due to TB.
Unlike CHE, the catastrophic total costs approach
which incorporates direct medical costs, direct non-
medical costs, and overall indirect costs highlights the
impact of income loss. It also provides a clearer descrip-
tion of the severity of the financial impact than the CHE
approach does. This is indicated by the consistently
higher mean gap in the TB and MDR-TB groups.
The determinants of catastrophic total costs shown in
this study highlight both the magnitude of the problem
of income loss and the need to address it properly. As
well as aggravating barriers to TB treatment adherence,
thereby potentially worsening TB outcomes, income loss
increases the risk of catastrophic costs and even greater
impoverishment. If a TB patient is the family breadwin-
ner, the incidence of catastrophic total costs is doubled.
In MDR-TB patients, coming from a poor household
was not a determinant of catastrophic total costs. We
had assumed that most MDR-TB cases would come
from poor households, but this proportion was in fact
very low. Overall, the incidence of catastrophic total
costs was also very high: irrespective of their income
level, over half of MDR-TB-affected households expe-
rienced such costs.
As our findings provide insights that contrast with
the perspective of CHE, they provide a new basis for es-
timating costs, and may thus have policy implications.
As well as supporting the WHO’s recommendation that
the catastrophic total costs approach should be used,
the main implication of our study is a strong recom-
mendation to government that it should introduce a
cost-mitigation policy and additional social protection
beyond free medical services [5, 17]. Forms of financial
protection other than food/nutritional supplementation
and travel vouchers may be required. Cash transfers
could be made conditional on behavioral requirements
such as continuing treatment. Microfinance programs
are also a potential form of financial support [32, 33],
but this strategy requires complex and expensive
inputs. The government should target beneficiaries
carefully, ensure the delivery to patients, provide incen-
tives that induce patients to adhere to treatment, and
should therefore consider reserving a budget that is
large enough. As well as emphasizing financial incen-
tives, it is imperative to tackle any stigma and discrim-
ination in workplaces that can lead to income loss. The
government should also strengthen the policy by sup-
porting job protection or paid sick leave for formally
employed TB patients.
The high incidence of catastrophic total costs among
poor patients requires inputs within the UHC frame-
work. The government should incorporate strategies for
widening population coverage, for improving the avail-
ability, accessibility, and quality of public health facilities;
and also for involving as many private health facilities as
possible in the BPJS network. To conform with the
ISTC, they should also ensure proper training.
This study has several limitations. First, in line with
the WHO protocol, we collected data from TB patients
who visited PHCs and excluded those who were
treated in facilities that were not linked to the NTP.
Neither did we include TB nor suspected TB patients
who were unable to afford TB-related services or who
dropped out of the diagnostic procedure or out of
treatment. This may have led to an underestimation of
the incidence of catastrophic total costs. Second,
MDR-TB patients were only recruited in a pulmonary
hospital in an urban area with a low proportion of
poor households. We did not describe a situation in
which patients were removed from the hospital to
PHCs for taking MDR-TB drugs after sputum conver-
sion, and dropped out from treatment. Third, although
we interviewed patients with a structured question-
naire to help recall their spending, our findings may
have been affected by recall biases. Finally, while our
study results apply to the western part of Indonesia
such as Java, Bali, and Sumatra, which constitute 80%
of the Indonesian population [34], some parts of
Indonesia may have different characteristics that re-
quire careful generalization, especially the islands and
more remote areas.
Table 6 Determinants of catastrophic total costs in TB cases (Continued)
Determinants Catastrophic total costs P cOR (95% CI) P aOR (95% CI)
Yes % No %
Food supplement
Yes 65 34 126 66 0.370 0.78 (0.5–1.3)
No 37 41 54 59 1.00
Adverse effect
Yes 53 43 71 57 0.029 1.77 (1.06–2.95) 0.089 1.77 (0.92–3.40)
No 49 31 109 69 1.00 1.00
cOR crude Odds Ratio, aOR adjusted Odds Ratio
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Table 7 Determinants of catastrophic total costs in MDR-TB cases
Determinants Catastrophic total costs P cOR (95% CI) P aOR (95% CI)
Yes % No %
Household income
Poor 19 83 4 17 0.974 0.98 (0.25–3.88)
Non-poor 34 83 7 17 1.00
Sex
Male 27 87 4 13 0.383 1.82 (0.48–6.95)
Female 26 79 7 21 1.00
Age in years
18–40 28 82 6 18 1.00
>40 25 83 5 17 0.917 1.07 (0.29–3.95)
Educational level
Low 9 75 3 25 1.00
Intermediate 35 83 7 17 0.515 1.67 (0.36–7.76)
High 9 90 1 10 0.378 3.00 (0.26–34.58)
Breadwinner
Patient 21 84 4 16 0.840 1.15 (0.30–4.41)
Not patient 32 82 7 18 1.00
Income-earning job
Yes 44 90 5 10 0.012 5.87 (1.47–23.47) 0.007 8.68 (1.81–41.70)
No 9 60 6 40 1.00 1.00
Job loss
Job loss 34 100 0 0 1.00
No job loss 19 63 11 37 0.998 0.00 (0.00-~)
Health insurance
Yes 46 82 10 18 1.00
No 7 87 1 13 0.709 1.52 (0.17–13.79)
HIV status
HIV negative 28 87 4 13 1.00
HIV not tested/unknown 25 78 7 22 0.331 0.51 (0.13–2.01)
Previous TB treatment
Yes 47 84 9 16 0.534 1.75 (0.29–2.01)
No 6 75 2 25 1.00
First contact facility
Private facility 10 100 0 0 0.266 8.66 (0.19–403.74)
Public facility 43 80 11 20 1.00
Hospitalization
Yes 30 88 4 12 0.235 2.27 (0.58–8.91) 0.090 3.92 (0.81–19.01)
No 23 77 7 23 1.00 1.00
Food supplement
Yes 41 84 8 16 0.741 1.28 (0.29–5.77)
No 12 80 3 20 1.00
Adverse effect
Yes 38 86 6 14 0.270 0.47 (0.13–1.79)
No 15 75 5 25 1.00
cOR crude Odds Ratio, aOR adjusted Odds Ratio
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Conclusions
Both TB and MDR-TB patients are in danger of falling into
even deeper poverty. Travel costs, food/nutritional supple-
mentation costs, and income loss all contribute to the inci-
dence of catastrophic total costs. This risk is higher in
patients from poor households, especially when they are
breadwinners who lose their jobs. These findings suggest
that measures beyond free medical services are required to
mitigate the financial burden of households affected by TB,
particularly for patients living in at-risk groups.
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